Ontify
⌘
S
⌘
S
Share
AZD1222
Vaxzevria
Viral vector vaccine for prevention of COVID-19.
Wikipedia | Oxford–AstraZeneca COVID-19 Vaccine
External Pages About AZD1222
Google Knowledge Graph
Statements about
AZD1222
Instance Of
Described by Source
Manufacturer
Developer
Oxford BioMedica
Funder
Government of the United Kingdom
Significant Event
Announcement Date
November 2020
Sponsor
Image
Official Name
Vaxzevria
(3/26/2021 - )
Start Time
:
3/26/2021
Subclass Of
AstraZeneca
AstraZeneca
AstraZeneca
Merck KGaA
Funded Product
University of Oxford
Coalition for Epidemic Preparedness Innovations
COVID-19 Vaccine
Adenovirus-Based Vaccine
Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial
A Study of a Candidate COVID-19 Vaccine (COV001)
A Phase III Study to Investigate a Vaccine Against COVID-19
Vaccine Candidate
HALIX B.V.
Oswaldo Cruz Foundation
A Phase I/II to Determine Efficacy, Safety and Immunogenicity of a Candidate COVID-19 Vaccine
Phase I/II Clinical Trial
(May 2020 - )
Start Time
:
May 2020
Number of Participants
:
543
Investigating a Vaccine Against COVID-19
Advent SRL
Serum Institute of India
Vaccines Manufacturing and Innovation Centre
Phase III Clinical Trial
(August 2020 - )
Start Time
:
August 2020
Number of Participants
:
30,000
Biomedical Advanced Research and Development Authority
Vaccitech
Jenner Institute
SK Bioscience
GAVI
Pall Corporation
Operation Warp Speed
Cobra Biologics (United Kingdom)
JCR Pharmaceuticals
Wikidata
